These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16159455)

  • 61. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
    Kanis JA; Johansson H; Oden A; McCloskey EV
    Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis.
    Halil M; Cankurtaran M; Yavuz BB; Ulger Z; Piskinpasa S; Gedik A; Haznedaroglu IC; Kirazli S; Ariogul S
    Ann Pharmacother; 2007 Jan; 41(1):41-5. PubMed ID: 17179188
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Postmenopausal osteoporosis and strontium ranelate.
    D'Haese PC; Santacruz F; De Broe ME
    N Engl J Med; 2004 May; 350(19):2001-3; author reply 2001-3. PubMed ID: 15128903
    [No Abstract]   [Full Text] [Related]  

  • 65. Strontium ranelate--data on vertebral and nonvertebral fracture efficacy and safety: mechanism of action.
    Kendler DL
    Curr Osteoporos Rep; 2006 Mar; 4(1):34-9. PubMed ID: 16527006
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women.
    Alexandersen P; Karsdal MA; Qvist P; Reginster JY; Christiansen C
    Bone; 2007 Jan; 40(1):218-22. PubMed ID: 17010685
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Current approaches to the diagnosis and treatment of postmenopausal osteoporosis].
    Baranova IA
    Ter Arkh; 2009; 81(10):56-60. PubMed ID: 19947443
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy of strontium ranelate on bone mineral density in men with osteoporosis.
    Ringe JD; Dorst A; Farahmand P
    Arzneimittelforschung; 2010; 60(5):267-72. PubMed ID: 20533764
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study.
    Silverman SL; Shen W; Minshall ME; Xie S; Moses KH
    J Rheumatol; 2007 Jan; 34(1):140-4. PubMed ID: 17216681
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis.
    Meunier PJ; Reginster JY
    Osteoporos Int; 2003; 14 Suppl 3():S66-76. PubMed ID: 12730769
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro.
    Bonnelye E; Chabadel A; Saltel F; Jurdic P
    Bone; 2008 Jan; 42(1):129-38. PubMed ID: 17945546
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prevention of vertebral fractures by strontium ranelate in postmenopausal women with osteoporosis.
    Compston J
    Osteoporos Int; 2005 Jan; 16 Suppl 1():S4-6. PubMed ID: 15480571
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis.
    Marquis P; Roux C; de la Loge C; Diaz-Curiel M; Cormier C; Isaia G; Badurski J; Wark J; Meunier PJ
    Osteoporos Int; 2008 Apr; 19(4):503-10. PubMed ID: 17929073
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Strontium ranelate: a new paradigm in the treatment of osteoporosis.
    Reginster JY; Lecart MP; Deroisy R; Lousberg C
    Expert Opin Investig Drugs; 2004 Jul; 13(7):857-64. PubMed ID: 15212623
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration.
    Boivin G; Deloffre P; Perrat B; Panczer G; Boudeulle M; Mauras Y; Allain P; Tsouderos Y; Meunier PJ
    J Bone Miner Res; 1996 Sep; 11(9):1302-11. PubMed ID: 8864905
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies.
    Reginster JY; Meunier PJ
    Osteoporos Int; 2003; 14 Suppl 3():S56-65. PubMed ID: 12730797
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Strontium ranelate in post-menopausal osteoporosis].
    Przedlacki J
    Endokrynol Pol; 2011; 62 Suppl 2():23-31. PubMed ID: 22125019
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A review of strontium ranelate and its effect on DXA scans.
    Blake GM; Lewiecki EM; Kendler DL; Fogelman I
    J Clin Densitom; 2007; 10(2):113-9. PubMed ID: 17485027
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Strontium ranelate--a promising therapeutic principle in osteoporosis.
    Boivin G; Doublier A; Farlay D
    J Trace Elem Med Biol; 2012 Jun; 26(2-3):153-6. PubMed ID: 22565017
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The new frontier of bone formation: a breakthrough in postmenopausal osteoporosis?
    Ruiz C; Abril N; Tarín JJ; García-Pérez MA; Cano A
    Climacteric; 2009 Aug; 12(4):286-300. PubMed ID: 19415543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.